Media Fills (Aseptic Process Simulation) Explained

A media fill, also called an aseptic process simulation (APS), is a test in which a sterile microbiological growth medium is run through an aseptic filling process in place of the product, then incubated and inspected for growth. If the process, environment and people are truly aseptic, every filled unit should stay clear.

It is the most direct evidence that an aseptic process can deliver sterile product. Aseptic filling relies on people, equipment and environment working together, and the media fill is how you prove they do.

For QC microbiologists and sterility assurance leads in India and the GCC, media fill records are also among the most scrutinised during inspections.

What the guidance expects

Two documents shape most media fill programmes. The first is EU GMP Annex 1, Manufacture of Sterile Medicinal Products, revised in 2022, which sets detailed expectations on APS design, frequency, acceptance and failure handling. PIC/S adopted the same text, so its influence reaches well beyond Europe.

The second is the US FDA guidance Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice (2004), widely used by manufacturers who export to the US.

Both agree on the principle: the simulation must imitate routine production as closely as possible, including its worst cases. Read the current text of each in full before writing or revising a protocol.

Designing a media fill around worst cases

A media fill that reproduces only a smooth, uneventful shift proves very little. The design should challenge the process with the conditions most likely to cause contamination, based on a documented risk assessment.

Annex 1 expects permitted interventions to be listed in procedures and included in the simulation, and expects operators to take part in a successful APS periodically. The number of units filled should also be justified against the batch size and interventions. Check the current text for exact requirements.

Media, incubation and inspection

The usual medium is soybean-casein digest medium (tryptone soya broth), which supports a broad range of bacteria and fungi. Each medium batch should pass a growth promotion test. Where filling is under inert gas or the process is anaerobic, the guidance asks you to consider an anaerobic medium.

Units are typically inverted or swirled so the medium contacts every internal surface, including the closure. Incubation of at least 14 days is common practice, often split across two temperature ranges such as 20-25 °C then 30-35 °C to favour both fungi and bacteria. Justify the temperatures, order and duration in your protocol.

Inspection should be done by trained personnel, and every unit filled must be accounted for. Any unit removed before incubation needs a documented reason. Unexplained gaps between units filled, incubated and inspected are a common inspection concern.

Acceptance criteria and frequency

Annex 1 sets a target of zero contaminated units. Under the 2022 text, any contaminated unit results in a failed APS, which must be investigated, corrected and followed by successful repeat simulations. The FDA 2004 guidance also targets zero and describes expected actions according to the number of units filled.

For frequency, the common expectation is an initial validation of several consecutive successful runs, then periodic revalidation, commonly twice a year for each line and process. Runs are also repeated after significant changes or a failure. Confirm exact numbers and triggers against the current Annex 1 text and your regulator.

Investigating a failed media fill

A positive unit shows that the process, as performed that day, allowed contamination. A good investigation covers:

• organism identification to species level, compared with environmental and personnel isolates
• the unit's position in the fill sequence, linked to the intervention log and video
• environmental monitoring data for the session
• gowning, personnel monitoring and training records
• sterilisation records for equipment, components and medium
• impact on commercial batches filled since the last successful run

Root cause tools such as the 5 Whys and fishbone diagrams help structure the analysis, but they depend on good data recorded during the run.

Worked example: a positive unit on a vial line in Hyderabad

A sterile injectables site in Hyderabad runs its six-monthly media fill on a vial line in a restricted access barrier system, with listed interventions, the slowest line speed, the largest vial size and all authorised operators across two shifts.

1. Detection: on day 9 of incubation, one vial is turbid. The unit number is recorded, QA is notified and the APS is declared failed.
2. Identification: the isolate is Staphylococcus epidermidis, a common human skin organism.
3. Trace-back: the intervention log shows the vial was filled just after a corrective intervention to clear a fallen stopper.
4. Supporting data: the glove print of the operator who performed it recovered the same species. Grade A air results were within limits.
5. Root cause: video shows the operator reached over an open vial, against procedure.
6. CAPA: the intervention is redesigned with a dedicated tool, operators are retrained and requalified, and QA assesses commercial batches filled since the last successful run.
7. Repeat: consecutive successful repeat runs, as required by the procedure and Annex 1, are completed before routine use resumes.

The investigation worked because of records made during the run: numbered units, a timed intervention log and video.

Common mistakes

• Designing the run around ideal conditions instead of worst cases.
• Omitting routine interventions, or performing them more carefully than normal.
• Removing units before incubation without a justified reason.
• Not reconciling units filled, incubated and inspected.
• Letting operators work aseptically without a successful APS.
• Treating a single positive unit as acceptable.
• Failing to assess commercial batches after a failed run.

Key takeaway: A media fill is only as strong as its worst-case design. Simulate real interventions and real people, aim for zero growth, and treat any contaminated unit as a signal that the aseptic process itself needs investigation.

Frequently Asked Questions

What is the difference between a media fill and a sterility test?

A sterility test examines a small sample from a finished batch, so it can detect only gross contamination. A media fill tests the aseptic process itself by filling a growth medium through the line and incubating the units. It gives far stronger assurance than a sterility test and is a key part of validating aseptic manufacture.

How often should media fills be performed?

The common expectation is an initial validation of several consecutive successful runs, then periodic revalidation, commonly twice a year for each aseptic process and filling line. Further runs are needed after significant changes or a failure. Confirm the exact frequency in the current EU GMP Annex 1 text and with your regulator, and write it into your procedure.

Which medium is used for a media fill?

Soybean-casein digest medium, also known as tryptone soya broth, is the usual choice because it supports a wide range of bacteria and fungi. Each medium batch should pass a growth promotion test. If the process uses an inert gas or anaerobic conditions, the guidance asks manufacturers to consider an anaerobic medium as well.

What is the acceptance criterion for a media fill?

The target is zero contaminated units. Under the 2022 revision of EU GMP Annex 1, any contaminated unit means the simulation has failed and must be investigated, with corrective action and successful repeat runs. The FDA 2004 aseptic processing guidance also targets zero and describes expected actions by number of units filled. Check the current texts for full detail.

Can a media fill be invalidated?

Invalidation is rare and needs strong documented evidence that the result does not reflect the process, for example proof that a unit was damaged after filling. Regulators are sceptical of invalidated media fills. In most cases a positive unit should be treated as a genuine failure and investigated in full, including the impact on commercial batches.

Next steps

If you work in sterile manufacturing or QC microbiology, our Pharmaceutical Microbiology & Contamination Control course covers aseptic processing, environmental monitoring and contamination control in depth, and Root Cause Analysis & CAPA builds the investigation skills a failed run demands. For related reading, see cleanroom environmental monitoring grades A to D, sterility testing basics and culture media quality control. You can also speak to a counsellor about the right learning path.